Herceptin breast cancer drug

Herceptin breast cancer drug

A617/0139 Rights Managed

Request low-res file

530 pixels on longest edge, unwatermarked

Request/Download high-res file

Uncompressed file size: 57.2MB

Downloadable file size: 1.8MB

Price image Pricing

Please login to use the price calculator


Caption: Herceptin breast cancer drug. Molecular model of the drug Herceptin (trastuzumab, pink and yellow) binding to the HER2 receptor (blue). HER2 (human epidermal growth factor receptor 2) is a receptor found on some breast cancer cells. Overabundance of HER2 makes cancer cells faster-growing and more likely to spread. Herceptin blocks these receptors by binding to them, greatly improving the chances of curing the cancer. Around 20% of breast cancers have HER2 over-expression, and are thus viable targets for the drug. In the UK in 2005, it was announced that all women with early breast cancer would be tested to see if their tumours would be receptive to Herceptin therapy.

Release details: Model release not required. Property release not required.

Keywords: 21st century, binding, biochemical, biochemistry, biological, biology, blocking, breast cancer, cancer drug, cancer treatment, chain, chains, chemical, chemistry, compound, compounds, drug, her2, herceptin, human body, human epidermal growth factor, medical, medicine, molecular, molecular model, molecule, molecules, monoclonal antibody, oncology, person, pharmacological, pharmacology, protein, proteins, receptor, trastuzumab

Licence fees: A licence fee will be charged for any media (low or high resolution) used in your project.